Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update

STOCKHOLM, Feb. 12, 2019 /PRNewswire/ --

Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year ended 31 December 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-end Report, on the same day at 09:00 a.m. CET. The event will be hosted by CEO Per Norlén and the presentation will be held in English.

When: 09:00 a.m. CET Thursday14 February 2019

Listen to the presentation: https://financialhearings.com/event/11461

To participate in the telephone conference, please use the dial in details shown below:

SE: +46856642692

UK: +443333009266

US: +18338230590

The conference call will be made available on the company's website after the call: http://www.alligatorbioscience.com.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has 50+ employees. For more information, please visit www.alligatorbioscience.com.

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

CONTACT:

For further information, please contact:

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46-46-540-82-06

E-mail: cecilia.hofvander@alligatorbioscience.com 

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/alligator-bioscience/r/alligator-bioscience-to-host-conference-call-to-provide-year-end-report-2018-business-update,c2739165

The following files are available for download: